<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060434</url>
  </required_header>
  <id_info>
    <org_study_id>Pento-LR</org_study_id>
    <nct_id>NCT03060434</nct_id>
  </id_info>
  <brief_title>Pentoxifylline and Lumbar Radiculopathy</brief_title>
  <official_title>Prospective Controlled Crossover Study of the Role of Pentoxifylline in the Management of Lumbar Radiculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Joseph University, Beirut, Lebanon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Joseph University, Beirut, Lebanon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective controlled crossover study is to evaluate the efficacy and
      safety of pentoxifylline per os (800 mg daily) in the management of lumbar radiculopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with lumbar radiculopathy, are recruited from senior author clinic. After
      verification of inclusion and exclusion criteria, patients consenting to enter the study are
      given 2 sequences (order randomly assigned) of treatment: Ibuprofen 600 mg bid, with
      paracetamol 1000 mg tid, pregabalin 75 mg bid for 15 days with pentoxifylline and 15 days
      without it. Basic clinical and demographical data are noted. Lumbar MRI results are also
      noted. Clinical evaluation of the patient is performed and included: clinical examination
      (including motor exam of lower limbs); pain is assessed according to Numerical rating Scale
      (NRS), and relative percentage of global improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each patient will receive for 1 month: Ibuprofen 600 mg bid; Paracetamol 1g tid if needed; pregabalin 75 mg bid pentoxifylline 400 mg bid will be added for either the first or second 15 days (randomization)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The assessor and the investigator are unaware of the sequence of the 15 days treatment with pentoxifylline</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical rating scale (NRS)</measure>
    <time_frame>From day 1 to 15</time_frame>
    <description>Pain assessment by NRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of improvement scale</measure>
    <time_frame>day 15 and 30</time_frame>
    <description>pain improvement scale from 1 to 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol consumption</measure>
    <time_frame>day 15 and 30</time_frame>
    <description>Total dose of paracetamol consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Day 15 and 30</time_frame>
    <description>Reporting side effects by patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lumbar Radiculopathy</condition>
  <condition>Lumbar Disc Herniation</condition>
  <condition>Lumbar Disc Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentoxifylline oral tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline Oral Tablet</intervention_name>
    <description>patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>Ibuprofen</other_name>
    <other_name>Paracetamol</other_name>
    <other_name>pregabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Paracetamol</other_name>
    <other_name>pregabalin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral lumbar radiculopathy

          -  Disc hernia confirming the diagnosis with radio-clinical concordance

        Exclusion Criteria:

          -  Radicular deficit needing surgery

          -  Cauda equine syndrome

          -  Absence of radio-clinical concordance on MRI

          -  Contraindication for anti-inflammatory (Hypertension, renal insufficiency, gastric
             ulcer â€¦)

          -  Previous intolerance to pentoxifylline, and/or to pregabalin and/or paracetamol

          -  Pregnancy

          -  Follow-up not possible

          -  Hepatic dysfunction

          -  History of drug abuse

          -  Current use of tramadol, codeine and/or morphine and its derivative

          -  Antidepressant use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Maarrawi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu de France Hospital - Beirut, Lebanon, 16 6830</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bilal Tarabay, MD</last_name>
    <phone>0096170829239</phone>
    <email>bila.tarabay@live.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Kobaiter, MSc, PhD</last_name>
    <phone>00961421678</phone>
    <email>s_kobaiter@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hotel Dieu de France Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>16 6830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>April 21, 2018</last_update_submitted>
  <last_update_submitted_qc>April 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Joseph University, Beirut, Lebanon</investigator_affiliation>
    <investigator_full_name>Dr Joseph Maarrawi</investigator_full_name>
    <investigator_title>Associate Professor : Researcher - Pain Specialist - Neurosurgeon</investigator_title>
  </responsible_party>
  <keyword>pentoxifylline</keyword>
  <keyword>Disc hernia</keyword>
  <keyword>sciatica</keyword>
  <keyword>lumbar radiculopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

